One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.
AMR Action Fund said this morning that the first two beneficiaries are Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals, two biotechs that according to AMR Action Fund chief executive Henry Skinner “are poised to change the treatment landscape for drug-resistant infections.”
A $1 billion fund backed by over 20 drugmakers made its first set of investments on Monday in two biotechnology startups to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.
A fund that plans to invest $1 billion in antibiotics companies has made its first two deals, backing startups aiming to tackle AMR in different ways. AMR Action Fund launched in 2020 to finance smaller biotechnology companies with antimicrobial drugs in clinical trials, bridging what it says is a funding gap between early research and regulatory approval.
A $1 billion fund backed by some of the world’s biggest drugmakers has made its first two investments in a bid to spur the development of new antibiotics and counter the rising threat of superbugs.
The AMR Action Fund has made its first two investments in the hopes of addressing the looming threat of antimicrobial resistance.
Venatorx Pharmaceuticals sold shares of its Series C Preferred Stock in a financing of undisclosed amount. Proceeds from the financing will be used to support the company as it advances its novel antibacterial portfolio through the drug development process.
The two companies represent different approaches to combating antimicrobial resistance (AMR). One is a more traditional antibiotic approach, while the other actually predates antibiotics.
A $1 billion public-private partnership seeking new antibiotics announced its first investments. The AMR Action Fund said it has invested in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.
The AMR Action Fund, backed by Big Pharmas such as Pfizer, Eli Lilly, Bayer and more, has selected the first beneficiaries of its $1 billion fund to address drug-resistant bacterial infections: Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.
Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections, including acute pyelonephritis.
Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.
Venatorx Pharmaceuticals has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of antimicrobial resistance.
A Chester County pharmaceutical company on Thursday announced positive results for its lead new drug candidate, an antibiotic under development to treat complicated urinary tract infections.
Complicated Urinary Tract Infections can be very challenging for clinicians to treat. These UTI do not respond to traditional, first-line therapies, and due to the nature of these bacterial infections, and patients' frequent underlying health conditions, they can be more susceptible to complications including sepsis.
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
Venatorx Pharmaceuticals’ mission to start restocking the thinning cupboard of antibiotics has advanced. With its experimental candidate hitting the primary endpoint in phase 3, Venatorx is preparing to file for FDA approval in patients with urinary tract infections by the end of the year.
The beta-lactam/beta-lactamase inhibitor combo surpassed noninferiority to standard meropenem in the phase III trial CERTAIN-1, demonstrating statistical superiority for the trial's composite endpoint of microbiologic and clinical response.
|You are using a browser that is not supported. Please consider changing your browser|